CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 31 enrolled
Drug / intervention
Silverlondevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04238728
NCT04238728Phase 1Completed
CompareCT.gov

An Unblinded, Open-label Study Evaluating the Safety of Silverlon to Manage Radiation Dermatitis.

University of Rochester·interventional·Posted Jan 23, 2020·Updated Jan 5, 2024

In Brief

A Phase 1 clinical trial evaluating Silverlon for Radiation Dermatitis. Completed, enrolled 31 participants across 1 site.

Detailed Summary

The purpose of this study is to see if a silver-nylon dressing (Silverlon®, Argentum Medical) is useful for the prevention or treatment of radiation dermatitis in patients receiving radiation therapy to the breast.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRadiation Dermatitis
CountriesUnited States
CollaboratorsBiomedical Advanced Research and Development Authority

Timeline

Phase 1CompletedFinished
2020202120222023202420252026
First PostedJan 23, 2020
Enrollment StartAug 31, 2020
Primary CompletionMar 1, 2022
Study CompletionMar 25, 2022
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 6.4 years ago

Interventions

Silverlondevice

silver nylon dressing will be applied daily